Abstract
Purpose :
The aim of the study is to evaluate the therapeutic response of diabetic macular edema combining intravitreal bevacizumab + macular micropulsed yellow 577 nm laser treatment.
Methods :
Patients from the Retina Department at "Hospital Nuestra Señora de la Luz" Mexico City diagnosed with diabetic macular edema were treated with intravitreal bevacizumab (monthly) + a single macular grid laser session with micropulsed yellow 577nm on the platform Iridex IQ 577. The parameters used: Spot: 100 microns / Lens: Volk Superquad / Power: 500 mW / Time: 200 ms / Duty cycle: 5%. At Month and 3 months of follow-up treatment we measured best corrected visual acuity (BCVA), central macular thickness (CMT) and macular volume (MV) with spectral domain Optical Coherence Tomography. Statistical Student t test was used to assess response to treatment.
Results :
Combined therapy after 1 month follow-up, achieved an improvement in BCVA of 0.12 logMAR , with a reduction of 407 microns to 366 microns in central macular thickness (CMT), a reduction on macular volume of 10.32 to 9.82 mm3 being an average of 0.5 mm3 after the first month of treatment, being similar at 3 months of follow up and statistically significant. (p< 0.05)
Conclusions :
Combined therapy in patients with diabetic macular edema is effective, being an alternative treatment therapy, antiangiogenic + macular yellow micropulsed laser.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.